|  |  |
| --- | --- |
| **Institution:** | Colorado Urology - St. Anthony |
| **Meeting Date:** | September 12, 2025 |
| **Meeting Time** | 11:30 AM Mountain Time |
| **Meeting Type:** | Virtual Platform Teleconference (Remote)Open to the Public |
| **Members in Attendance:** |

|  |  |  |
| --- | --- | --- |
| **Member** | **Voting** | **Member Type** |
| Hauke, Caitlyn | Yes | Chair: Biosafety Expert/HGT Expert |
| Rastein, Daniel | Yes | Core Member: Biosafety Expert/HGT Expert |
| Reed, Craig | Yes | Core Member: Biosafety Expert/HGT Expert |
| Vance, James | Yes | Local Unaffiliated Member |
| Aggers, Deborah | No | Site Contact |

 |
| **Invited Members Not in Attendance:** |

|  |  |  |
| --- | --- | --- |
| **Member** | **Voting** | **Member Type** |
| Wilson, Zachary | Yes | Local Unaffiliated Member |

 |
| **Guests**: | None  |
| **Staff:** | Payne, Kaylie |

**Call to Order:** The IBC Chair called the meeting to order at 11:30 AM. A quorum was present as defined in the Sabai IBC Charter.

**Conflicts of Interest:** The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

**Public Comments:** No public comments were made prior to or at the meeting.

**Review of Prior Business:** None

**Previous Meeting Minutes**: Previous meeting minutes from **11/12/24** were reviewed and approved with no changes requested.

**New Business:**

|  |  |
| --- | --- |
| **PI:** | Cahn, David MD |
| **Sponsor:** | CG Oncology, Inc |
| **Protocol:** | BOND-003A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG) |
| **Review Type:** | Annual Review |
| **NIH Guidelines Section:** | III-C-1 |

**Trial Summary:** BOND-003 is a Phase III clinical trial sponsored by CG Oncology Inc. and

designed to assess the safety and efficacy of a recombinant, conditionally replicating oncolytic

adenovirus designed to express human granulocyte-macrophage colony-stimulating factor (GMCSF) in adults with Non-Muscle Invasive Bladder Cancer (NMIBC) that is unresponsive to

standard-of-care therapy with Bacillus Calmette-Guerin (BCG). The investigational product (IP) is administered by intravesical instillation into the bladder.

**Biosafety Containment Level (BSL):** The study agent cretostimogene is based on a

recombinant Risk Group 2 virus containing more than two-thirds of the native genome, requiring

the use of BSL-2 containment under the NIH Guidelines.

**Risk Assessment and Discussion:**

* The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
	+ In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, aerosols and needlesticks of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices including Standard Precautions and sharps safety and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
	+ The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
	+ The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
	+ The Site confirmed that staff members receive Bloodborne Pathogens training.
	+ Occupational Health Recommendations: The Sponsor notes that individuals who are at a potentially higher risk from working with or handling the study agent, such as pregnant or breastfeeding women and immunosuppressed or immunocompromised individuals, should not prepare, administer, or otherwise handle the study agent or materials contaminated with the study agent or provide direct care for treated participants presenting with any symptoms of illness attributed to cretostimogene for at least 1 week after treatment or until complete resolution of symptoms.
	+ The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
* The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
	+ The Site verified that the information provided by the Chair was accurate.
	+ In response to a question from the Committee, the Site confirmed that their biosafety cabinet is unable to be certified appropriately and therefore, only benchtop preparation will be conducted. The Committee had no concerns.

**Motion:** A motion of Full Approval for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

* Contingencies stated by the Committee: None
* Stipulations stated by the Committee: None

**New Business:**

|  |  |
| --- | --- |
| **PI:** | Cahn, David MD |
| **Sponsor:** | CG Oncology, Inc |
| **Protocol:** | CORE-008A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) |
| **Review Type:** | Annual Review |
| **NIH Guidelines Section:** | III-C-1 |

**Trial Summary:** CORE-008 is a multi-arm, open-label Phase II trial sponsored by CG Oncology,

Inc. and designed to assess the safety and efficacy of cretostimogene grenadenorepvec in

participants with high-risk non-muscle invasive bladder cancer. The study agent cretostimogene

grenadenorepvec consists of a recombinant, conditionally replicating oncolytic adenovirus. The investigational product (IP) is administered by intravesical instillation into the bladder.

**Biosafety Containment Level (BSL):** The study agent cretostimogene is based on a

recombinant Risk Group 2 virus containing more than two-thirds of the native genome, requiring

the use of BSL-2 containment under the NIH Guidelines.

**Risk Assessment and Discussion:**

* The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
	+ In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, aerosols and needlesticks of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices including Standard Precautions and sharps safety and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
	+ The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
	+ The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
	+ The Site confirmed that staff members receive Bloodborne Pathogens training.
	+ Occupational Health Recommendations: The Sponsor notes that individuals who are at a potentially higher risk from working with or handling the study agent, such as pregnant or breastfeeding women and immunosuppressed or immunocompromised individuals, should not prepare, administer, or otherwise handle the study agent or materials contaminated with the study agent or provide direct care for treated participants presenting with any symptoms of illness attributed to cretostimogene for at least 1 week after treatment or until complete resolution of symptoms.
	+ The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
* The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
	+ The Site verified that the information provided by the Chair was accurate.
	+ In response to a question from the Committee, the Site confirmed that their biosafety cabinet is unable to be certified appropriately and therefore, only benchtop preparation will be conducted. The Committee had no concerns.

**Motion:** A motion of Full Approval for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

* Contingencies stated by the Committee: None
* Stipulations stated by the Committee: None

**New Business:**

|  |  |
| --- | --- |
| **PI:** | Cahn, David MD |
| **Sponsor:** | CG Oncology, Inc |
| **Protocol:** | CRETO-EAPAn Expanded Access Program of Cretostimogene Grenadenorepvec in Participants with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) |
| **Review Type:** | Annual Review |
| **NIH Guidelines Section:** | III-C-1 |

**Trial Summary:** CRETO-EAP is an open-label, expanded access trial (EAP) sponsored by CG

Oncology, Inc. and designed to provide access to cretostimogene grenadenorepvec, a

recombinant, conditionally replicating oncolytic adenovirus, in patients with non-muscle invasive

bladder cancer (NMIBC) unresponsive to BCG. The investigational product (IP) is administered by intravesical instillation into the bladder.

**Biosafety Containment Level (BSL):** The study agent cretostimogene is based on a

recombinant Risk Group 2 virus containing more than two-thirds of the native genome, requiring

the use of BSL-2 containment under the NIH Guidelines.

**Risk Assessment and Discussion:**

* The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
	+ In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, aerosols and needlesticks of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices including Standard Precautions and sharps safety and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
	+ The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
	+ The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
	+ The Site confirmed that staff members receive Bloodborne Pathogens training.
	+ Occupational Health Recommendations: The Sponsor notes that individuals who are at a potentially higher risk from working with or handling the study agent, such as pregnant or breastfeeding women and immunosuppressed or immunocompromised individuals, should not prepare, administer, or otherwise handle the study agent or materials contaminated with the study agent or provide direct care for treated participants presenting with any symptoms of illness attributed to cretostimogene for at least 1 week after treatment or until complete resolution of symptoms.
	+ The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
* The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
	+ The Site verified that the information provided by the Chair was accurate.
	+ In response to a question from the Committee, the Site confirmed that their biosafety cabinet is unable to be certified appropriately and therefore, only benchtop preparation will be conducted. The Committee had no concerns.

**Motion:** A motion of Full Approval for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

* Contingencies stated by the Committee: None
* Stipulations stated by the Committee: None

**New Business:**

|  |  |
| --- | --- |
| **PI:** | Cahn, David MD  |
| **Sponsor:** | CG Oncology, Inc  |
| **Protocol:** | PIVOT-006A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT) |
| **Review Type:** | Annual Review |
| **NIH Guidelines Section:** | III-C-1 |

**Trial Summary:** PIVOT-006 is an open-label, randomized, Phase III clinical trial sponsored by

CG Oncology designed to assess the safety and efficacy of cretostimogene grenadenorepvec

(“cretostimogene”; previously known as CG0070) in adults with intermediate-risk non-muscle

invasive bladder cancer (IR-NMIBC). Cretostimogene is a recombinant, conditionally replicating

oncolytic adenovirus engineered to express human granulocyte-macrophage colony-stimulating

factor (GM-CSF). The investigational product (IP) is administered by intravesical instillation into the bladder.

**Biosafety Containment Level (BSL):** The study agent cretostimogene is based on a

recombinant Risk Group 2 virus containing more than two-thirds of the native genome, requiring

the use of BSL-2 containment under the NIH Guidelines.

**Risk Assessment and Discussion:**

* The Committee reviewed the clinical trial Sponsor’s study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
	+ In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills, splashes, aerosols and needlesticks of the IP during preparation and/or administration procedures. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices including Standard Precautions and sharps safety and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
	+ The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.
	+ The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
	+ The Site confirmed that staff members receive Bloodborne Pathogens training.
	+ Occupational Health Recommendations: The Sponsor notes that individuals who are at a potentially higher risk from working with or handling the study agent, such as pregnant or breastfeeding women and immunosuppressed or immunocompromised individuals, should not prepare, administer, or otherwise handle the study agent or materials contaminated with the study agent or provide direct care for treated participants presenting with any symptoms of illness attributed to cretostimogene for at least 1 week after treatment or until complete resolution of symptoms.
	+ The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.
* The Committee reviewed the Site’s facility details, relevant study-specific procedures and practices, the Annual Review Report and other applicable information provided by the Site for the purposes of the IBC review.
	+ The Site verified that the information provided by the Chair was accurate.
	+ In response to a question from the Committee, the Site confirmed that their biosafety cabinet is unable to be certified appropriately and therefore, only benchtop preparation will be conducted. The Committee had no concerns.

**Motion:** A motion of Full Approval for the study at BSL-2 was passed by unanimous vote. There were no votes against and no abstentions.

* Contingencies stated by the Committee: None
* Stipulations stated by the Committee: None

**Review of Incidents:** Nothing to report.

**IBC Training:** Nothing to report.

**Reminder of IBC Approval Requirements.**

**Adjournment:** The IBC Chair adjourned the meeting at 12:15 PM

**Post-Meeting Pre-Approval Note:** None